Literature DB >> 29955494

Clinical potential of psilocybin as a treatment for mental health conditions.

Jeremy Daniel1, Margaret Haberman2.   

Abstract

Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including depressed mood, anxiety disorders, obsessive-compulsive disorder, alcohol use disorder, and tobacco use disorder. This article provides an in-depth review of the study design and results of psilocybin in each of these conditions and discusses the clinical potential for use.

Entities:  

Keywords:  addiction; alcohol; anxiety; depression; hallucinogen; obsessive-compulsive disorder; psilocybin; psychedelic; tobacco

Year:  2018        PMID: 29955494      PMCID: PMC6007659          DOI: 10.9740/mhc.2017.01.024

Source DB:  PubMed          Journal:  Ment Health Clin        ISSN: 2168-9709


  17 in total

1.  Psilocybin and Obsessive Compulsive Disorder.

Authors:  James Allen Wilcox
Journal:  J Psychoactive Drugs       Date:  2014 Nov-Dec

Review 2.  The pharmacology of psilocybin.

Authors:  Torsten Passie; Juergen Seifert; Udo Schneider; Hinderk M Emrich
Journal:  Addict Biol       Date:  2002-10       Impact factor: 4.280

3.  Psychedelics not linked to mental health problems or suicidal behavior: a population study.

Authors:  Pål-Ørjan Johansen; Teri Suzanne Krebs
Journal:  J Psychopharmacol       Date:  2015-03-05       Impact factor: 4.153

4.  Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.

Authors:  Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman
Journal:  J Psychopharmacol       Date:  2015-01-13       Impact factor: 4.153

5.  Psilocybin, psychological distress, and suicidality.

Authors:  Peter S Hendricks; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-09       Impact factor: 4.153

6.  Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.

Authors:  Erich Studerus; Michael Kometer; Felix Hasler; Franz X Vollenweider
Journal:  J Psychopharmacol       Date:  2010-09-20       Impact factor: 4.153

Review 7.  Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.

Authors:  David Baumeister; Georgina Barnes; Giovanni Giaroli; Derek Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2014-08

8.  Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.

Authors:  Matthew W Johnson; Albert Garcia-Romeu; Mary P Cosimano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2014-09-11       Impact factor: 4.153

9.  Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.

Authors:  Robin L Carhart-Harris; David Erritzoe; Tim Williams; James M Stone; Laurence J Reed; Alessandro Colasanti; Robin J Tyacke; Robert Leech; Andrea L Malizia; Kevin Murphy; Peter Hobden; John Evans; Amanda Feilding; Richard G Wise; David J Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

Review 10.  Recreational use, analysis and toxicity of tryptamines.

Authors:  Roberta Tittarelli; Giulio Mannocchi; Flaminia Pantano; Francesco Saverio Romolo
Journal:  Curr Neuropharmacol       Date:  2015-01       Impact factor: 7.363

View more
  7 in total

1.  Ancient medicinal plants of South America.

Authors:  Christine VanPool
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-21       Impact factor: 11.205

Review 2.  Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression.

Authors:  Susan Ling; Felicia Ceban; Leanna M W Lui; Yena Lee; Kayla M Teopiz; Nelson B Rodrigues; Orly Lipsitz; Hartej Gill; Mehala Subramaniapillai; Rodrigo B Mansur; Kangguang Lin; Roger Ho; Joshua D Rosenblat; David Castle; Roger S McIntyre
Journal:  CNS Drugs       Date:  2021-11-17       Impact factor: 5.749

3.  Virtual Reality and Psychedelics for the Treatment of Psychiatric Disease: A Systematic Literature Review.

Authors:  Federico J Gómez-Busto; Mario I Ortiz
Journal:  Clin Neuropsychiatry       Date:  2020-12

Review 4.  Will psilocybin lose its magic in the clinical setting?

Authors:  Caroline Hayes; Mourad Wahba; Stuart Watson
Journal:  Ther Adv Psychopharmacol       Date:  2022-04-22

Review 5.  Secrets of Flavonoid Synthesis in Mushroom Cells.

Authors:  Jan Pukalski; Dariusz Latowski
Journal:  Cells       Date:  2022-09-29       Impact factor: 7.666

Review 6.  The Therapeutic Potential of Psilocybin.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Henkel Valentine; Justin Grant; Amza Ali; Wilfred Ngwa; Lorenzo Gordon
Journal:  Molecules       Date:  2021-05-15       Impact factor: 4.411

Review 7.  Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.

Authors:  Elaine Meade; Sarah Hehir; Neil Rowan; Mary Garvey
Journal:  J Fungi (Basel)       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.